FISH for Ewing's Sarcoma Test Cost & Procedure

Overview

When utilized in conjunction with an anatomic pathology consultation, aiding thin the distinguishing confirmation of Ewing sarcoma (EWS)/primitive neuroectodermal tumor, myxoid chondrosarcoma, desmoplastic little, circular cell tumor, clear cell sarcoma, and myxoid liposarcoma.

When the results of the reverse transcriptase-polymerase chain reaction are ambiguous or do not reflect the clinical picture, it can help with the diagnosis of EWS.

Algorithm testing

A pathology discussion isn't a portion of this test. In case a pathology meeting is required, a PATHC / Pathology Discussion ought to be organized, and the desired fluorescence in situ hybridization (Angle) test will be asked and performed at an additional taken toll.

There is a fee associated with this test that covers the application of the first probe set (2 FISH probes) and expert evaluation of the data. Any reflex probing procedures will result in additional fees. Based on the number of cells examined by each probe set, analysis fees will be payable. There won't be any analysis fees if there are no cells available for analysis.

For specific information, go to the Procedure Description.

Type of specimen tissue

Shipping requirements

Inform Express Mail or a comparable service if you do not use a courier.

Important information

1. A pathology report is necessary to conduct testing. Working draughts, initial pathology reports, and surgical pathology reports are all acceptable types of pathology reports.

2. A justification for the test must be given. An adequate indication for testing should be given if this information is not given.

Controlled information

Primitive neuroectodermal cancers, including Ewing sarcoma, are small, round-cell tumors there hypothesized to develop from cells with varying degrees of differentiation from primitive neuroectodermal origin. Small, round cell tumors include desmoplastic small, round cell tumors, poorly differentiated synovial sarcomas, and rhabdomyosarcomas. Recent molecular studies have demonstrated the specificity of molecular markers in discriminating certain subtypes of tiny, round blue-cell tumors, even though immunohistochemistry markers can be useful in the accurate identification of these cancers. Each tumor type must be accurately diagnosed to handle patients clinically.

A rearrangement of the EWSR1 gene at 22q12 with FLI1 at 11q24 (t[11;22]) or ERG at 21q22 is present in 85% and 5% to 10% of Ewing Ewingtumors actively(t[21;22]). Less frequently than 1% of the time, additional fusion ppaperssuchchas  ETV1 at 7p22, E1AF at 17q12, or FEV at 2q33 may be present.